Literature DB >> 23372968

Intracranial phosphaturic mesenchymal tumor, mixed connective tissue variant presenting without oncogenic osteomalacia.

Regina S Bower1, Wilson P Daugherty, Caterina Giannini, Ian F Parney.   

Abstract

BACKGROUND: Phosphaturic mesenchymal tumor, mixed connective tissue variant (PMTMCT) is a rare tumor typically occurring in soft tissues and bone, causing oncogenic (tumor-induced) osteomalacia (TIO) through secretion of the phosphaturic hormone, fibroblast growth factor-23 (FGF-23). Rare tumors identical to PMTMCT occur without known TIO. Intracranial localization of PMTMCT is extremely rare, with only two cases reported in the literature. We present a very unusual case of a patient with an intracranial PMTMCT that presented with neurologic changes without osteomalacia. CASE DESCRIPTION: A 67-year-old woman presented with progressive incontinence, apathy, and abulia after having undergone a total knee replacement 1 month earlier. Imaging disclosed a large left frontal anterior fossa mass. She underwent uncomplicated surgical resection of this tumor. Surprisingly, histopathology suggested PMTMCT. Reverse transcription polymerase chain reaction (RT-PCR) assay demonstrating FGF-23 expression in the tumor confirmed the diagnosis. Serum FGF-23 levels postoperatively were normal and she had no clinical or laboratory evidence of osteomalacia or phosphaturia.
CONCLUSION: This report should serve to alert clinicians to the possibility that PMTMCT can be included in the differential diagnosis of intracranial masses even in the absence of tumor-induced osteomalacia.

Entities:  

Keywords:  Intracranial; neoplasm; neuropathology; oncogenic osteomalacia

Year:  2012        PMID: 23372968      PMCID: PMC3551505          DOI: 10.4103/2152-7806.104745

Source DB:  PubMed          Journal:  Surg Neurol Int        ISSN: 2152-7806


  17 in total

1.  [Rickets following bone tumor].

Authors:  A PRADER; R ILLIG; E UEHLINGER; G STALDER
Journal:  Helv Paediatr Acta       Date:  1959-12

2.  Phosphaturic mesenchymal tumour-mixed connective tissue variant without oncogenic osteomalacia.

Authors:  R Winters; S Bihlmeyer; L McCahill; K Cooper
Journal:  J Clin Pathol       Date:  2009-08       Impact factor: 3.411

3.  Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia.

Authors:  D J Evans; J G Azzopardi
Journal:  Lancet       Date:  1972-02-12       Impact factor: 79.321

4.  Osteomalacia cured by surgery.

Authors:  A Furco; M Roger; B Mouchet; O Richard; X Martinache; A Fur
Journal:  Eur J Intern Med       Date:  2002-02       Impact factor: 4.487

5.  Neoplastic pathology of oncogenic osteomalacia/rickets.

Authors:  N Weidner; R S Bar; D Weiss; M P Strottmann
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

6.  Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the thoracic spine.

Authors:  Elena Pirola; Francesco Vergani; Paolo Casiraghi; Eugenio Biagio Leone; Paolo Guerra; Erik Pietro Sganzerla
Journal:  J Neurosurg Spine       Date:  2009-04

7.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

8.  August 2003: 47-year-old female with a 7-year history of osteomalacia and hypophosphatemia.

Authors:  Jorge S Reis-Filho; Maria E Paiva; José M Lopes
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

Review 9.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

10.  Hypophosphatemic oncogenic osteomalacia: report of three new cases.

Authors:  M Papotti; M P Foschini; G Isaia; G Rizzi; C M Betts; V Eusebi
Journal:  Tumori       Date:  1988-10-31
View more
  4 in total

1.  Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy.

Authors:  Valentina D Tarasova; Alejandro G Trepp-Carrasco; Robert Thompson; Robert R Recker; William H Chong; Michael T Collins; Laura A G Armas
Journal:  J Clin Endocrinol Metab       Date:  2013-09-06       Impact factor: 5.958

2.  Sinonasal phosphaturic mesenchymal tumor: Case report and systematic review.

Authors:  Nicholas L Deep; Rachel B Cain; Ann E McCullough; Joseph M Hoxworth; Devyani Lal
Journal:  Allergy Rhinol (Providence)       Date:  2014-01

Review 3.  Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review.

Authors:  Huanwen Wu; Marilyn M Bui; Lian Zhou; Dongmei Li; Hui Zhang; Dingrong Zhong
Journal:  Mod Pathol       Date:  2018-09-11       Impact factor: 7.842

4.  CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: A case report.

Authors:  Zhenshan Shi; Yiqiong Deng; Xiumei Li; Yueming Li; Dairong Cao; Vikash Sahadeo Coossa
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.